Summary
This prediction ended on 11.03.24 with a price of €26.78. With a performance of -6.87%, the SELL prediction for Bayer AG by Traumtanz was down slightly. Traumtanz has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Bayer AG | -1.401% | -1.401% | 109.845% |
| iShares Core DAX® | 1.066% | -0.525% | 9.662% |
| iShares Nasdaq 100 | -0.493% | -4.055% | -0.132% |
| iShares Nikkei 225® | -2.028% | 6.911% | 26.863% |
| iShares S&P 500 | -0.103% | -2.366% | 0.508% |
According to Traumtanz what are the pros and cons of Bayer AG for the foreseeable future?
Pros
Top 10 in its market
Future proof or reliable business model
Medium risks for its business
Capable Management
Higher EBIT margin than peer group
Fair valuation
High dividend yield expected
positive Cash Flow expected
Good rating
Valuable balance sheet
ROE higher than 10% per year
Normal challenges to pay loans and raise capital
Innovative
Differentiated customer and product portfolio
Sustainability is important
Some uniques
Small cyclical dependencies
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
Standard Investments for future growth
Good culture
Growths faster than the competition
Known brand
EBIT growth >5% per year expected
Stable Large shareholder and/or long term investor
